Lasa Supergenerics profit and loss

Latest FY26

Revenue: ₹25.1cr−82.4% on FY25
EBITDA: −₹28.4cr₹6.3 cr in FY25
Net profit: −₹34.1cr−₹14.8 cr in FY25
EPS: −₹6.80−₹2.95 in FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	6.4	25.1	142	104	130	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.2	0.2	5.0	0.1	1.8
	6.5	25.3	147	104	131
	6.6	19.1	108	79.3	110
	3.4	4.7	−1.9	−4.1	−4.0
	1.2	2.2	6.1	6.3	7.4
	0.5	0.4	2.7	1.9	4.2
	6.0	6.0	12.3	10.7	13.4
	3.9	27.5	23.9	20.6	22.7
	21.6	59.9	151	115	154
	−8.7	−28.4	6.3	2.2	−6.6
	−14.7	−34.4	−6.0	−8.5	−20.0
Profit
	−15.1	−34.6	−3.7	−10.3	−22.4
	−0.5	0.0	−15.7	−8.8	−19.9
	−15.5	−34.6	−19.4	−19.1	−42.3
	1.0	−0.5	−4.6	2.6	−3.7
	1.0	−0.5	−4.6	2.6	−3.7
	0.0	0.0	0.0	0.0	−0.0
	−16.5	−34.1	−14.8	−21.7	−38.6
	−16.5	−34.1	−14.8	−21.7	−38.6
	0.0	0.0	0.0	0.1	0.0
	−16.5	−34.1	−14.7	−21.6	−38.6
Per share
	−₹3.30	−₹6.80	−₹2.95	−₹4.34	−₹15.42
	−₹3.30	−₹6.80	−₹2.95	−₹4.34	−₹15.42
Other comprehensive income — detail
	—	—	0.0	—	—
	—	—	0.0	—	—
Per share — as-filed variants
	−₹3.30	−₹6.80	−₹2.95	−₹4.34	−₹7.71
	−₹3.30	−₹6.80	−₹2.95	−₹4.34	−₹7.71
	₹0.00	₹0.00	₹0.00	₹0.00	−₹7.71
	₹0.00	₹0.00	₹0.00	₹0.00	−₹7.71
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	−3.6	1.3	36.3	29.1	23.5
	−57.2%	5.2%	25.5%	27.9%	18.1%
Adjusted (ex-exceptional items) — derived
	−15.1	−34.6	−3.7	−10.3	−22.4
	−0.5	0.0	−15.7	−8.8	−19.9
	−16.1	−34.1	−2.8	−13.0	−20.5
	−₹3.20	−₹6.80	−₹0.57	−₹2.59	−₹8.17

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

LASA₹4.67

Lasa Supergenerics Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersMANGALAM BIOFILCHEM ORTINGLOBE VINEETLAB KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹23.4 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	129.6	104.3	142.4	25.1	6.4
Other Income	1.8	0.1	5.0	0.2	0.2
Total Income	131.4	104.4	147.5	25.3	6.5
Expenses
+ Cost of Materials Consumed	110.1	79.3	108.1	19.1	6.6
+ Changes in Inventories	-4.0	-4.1	-1.9	4.7	3.4
+ Employee Benefit Expense	7.4	6.3	6.1	2.2	1.2
+ Finance Costs	4.2	1.9	2.7	0.4	0.5
+ Depreciation & Amortisation	13.4	10.7	12.3	6.0	6.0
+ Other Expenses	22.7	20.6	23.9	27.5	3.9
Total Expenses	153.7	114.8	151.2	59.9	21.6
EBITDA	-6.6	2.2	6.3	-28.4	-8.7
EBIT	-20.0	-8.5	-6.0	-34.4	-14.7
Profit
PBT before Exceptional Items	-22.4	-10.3	-3.7	-34.6	-15.1
+ Exceptional Items	-19.9	-8.8	-15.7	0.0	-0.5
Pretax Income	-42.3	-19.1	-19.4	-34.6	-15.5
+ Deferred Tax	-3.7	2.6	-4.6	-0.5	1.0
Tax Expense	-3.7	2.6	-4.6	-0.5	1.0
+ Net Movement in Regulatory Deferral Balances	-0.0	0.0	0.0	0.0	0.0
Net Income	-38.6	-21.7	-14.8	-34.1	-16.5
+ Net Income — Continuing Ops	-38.6	-21.7	-14.8	-34.1	-16.5
+ Other Comprehensive Income	0.0	0.1	0.0	0.0	0.0
Total Comprehensive Income	-38.6	-21.6	-14.7	-34.1	-16.5
Per Share
Basic EPS	-15.42	-4.34	-2.95	-6.80	-3.30
Diluted EPS	-15.42	-4.34	-2.95	-6.80	-3.30
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	0.0	—	—
+ Items NOT to be Reclassified to P&L	—	—	0.0	—	—
Per Share — as-filed variants
Basic EPS — Continuing Operations	-7.71	-4.34	-2.95	-6.80	-3.30
Diluted EPS — Continuing Operations	-7.71	-4.34	-2.95	-6.80	-3.30
Basic EPS — Discontinued Operations	-7.71	0.00	0.00	0.00	0.00
Diluted EPS — Discontinued Operations	-7.71	0.00	0.00	0.00	0.00
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	23.5	29.1	36.3	1.3	-3.6
Gross Margin %	18.10	27.91	25.46	5.16	-57.16
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-22.4	-10.3	-3.7	-34.6	-15.1
− Exceptional Items (reconciliation)	-19.9	-8.8	-15.7	0.0	-0.5
Net Income Adj (tax-effected)	-20.5	-13.0	-2.8	-34.1	-16.1
EPS Adj	-8.17	-2.59	-0.57	-6.80	-3.20
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	50.1	50.1	50.1	50.1	50.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.